Information Provided By:
Fly News Breaks for February 25, 2019
BLUE
Feb 25, 2019 | 16:44 EDT
Cowen analyst Yaron Werber assumed coverage on Bluebird Bio with an Outperform. The analyst believes that investors should have a strong interest in the stock, as bluebird has a deep pipeline, and is launching three drugs in 2019-2020, with "a slew of data" coming in 2019.